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Introduction
Systemic inflammation is comorbid with various diseases including diabetes (64) , cancer (14), heart disease (66) , and sepsis (29, 30) , and it plays a prominent role in eight out of the ten leading causes of death in the U.S. (28) . The action of inflammation is multi-faceted and impacts multiple organ systems, such as the digestive, respiratory, endocrine, and nervous systems. In this study, we use mathematical modeling to explore how the inflammatory response to a pathogen challenge interacts with the thermal, pain perception, and cardiovascular systems. Our goal is to examine the effect on cytokine concentrations, body temperature, pain, heart rate (HR), and blood pressure (BP). We focus on hemodynamic quantities that are routinely collected at both in-and out-patient facilities, measured non-invasively at a high sampling rate, and interpreted within minutes. We hypothesize that the hemodynamic signals correlate with inflammatory markers, and therefore have the potential to inform the development of clinical protocols important for early detection of pathological conditions such as sepsis. Understanding how hemodynamics change with inflammation is also of great importance in devising more effective treatment strategies to improve recovery outcomes for patients.
Numerous in-vivo biological studies in mice and rats have investigated the effects of autonomic control on the inflammatory system (56, 57) . Borovikova et al. (5) discovered the cholinergic anti-inflammatory pathway modulating the immune response via the local release of acetylcholine from vagal fibers in target tissues. They found that an increase in vagal activity results in a decrease in the pro-inflammatory cytokines tumor necrosis factor-(TNF-), interleukin 6 (IL-6), and interleukin 1 (IL-1 ). Following this, Tracey (57) found that the production of cytokines in response to inflammation activates afferent firing to the brain, and that subsequent vagal efferent activation inhibits cytokine synthesis. This inflammation-sensing and inflammation-suppressing network, dubbed the inflammatory reflex, explains how the autonomic control and inflammatory systems work synergistically to maintain homeostasis of the inflammatory response. The study by Tracey (57) did an excellent job describing the impact of the autonomic control on inflammation, but it did not describe how changes in autonomic regulation, triggered by inflammation, impact hemodynamics. While the above investigations (10, 15, 47) revealed essential features of the immune reaction to pathogens in rodents, they do not elucidate how the inflammatory system interacts with the cardiovascular, thermal, and pain systems. Moreover, it is well known that the inflammatory pathways differ between rodents and humans (54) and that rodents tolerate much higher levels of pathogens (17) . Experimental observations by Copeland et al. (13) demonstrated this by administering LPS to humans and mice at doses (2 ng/kg of body weight for humans and 500 ng/kg for mice) eliciting equivalent IL-6 plasma concentrations 2 hours post-injection. Their results showed that humans experienced fever as well as an increase in HR and systolic BP, while the mice had no fever or changes in HR and BP. These results demonstrate that investigations in mice do not have direct applicability to humans. New models are needed to effectively explore the differences between the two species and to gain insight into thermal regulation and cardiovascular functions.
Several studies have used models to examine inflammatory-cardiovascular communication in humans (18, 52) . Foteinou et al. (18) employed a multi-scale mathematical model to predict the parasympathetic activity and HR in human subjects who received a dose of LPS (2 ng/kg of body weight) alone or in combination with an epinephrine infusion. This study assessed parasympathetic activity via calculations of the heart rate variability (HRV) index pNN50, which measures the percentage of differences of successive inter-beat intervals greater than 50 ms (18). Scheff et al. (52) expanded this model by incorporating regulation of immune activity via hormonal circadian rhythms. They showed that circadian variability in inflammation correlates with daily patterns in HR and HRV (52) . While the investigations of Foteinou et al. (18) and Scheff et al. (52) reflect the complexity of inflammatory-cardiac interactions, they do not account for thermal and pain regulation and the impact on hemodynamics.
As the body battles infection the threshold for pain perception decreases (2, 13, 31, 63) , and the release of inflammatory cytokines, in particular, IL-6 and TNF-, raises core temperature (61) . Results by Copeland et al. (13) showed that during a pathogen challenge in humans, the change in BP and temperature plays a vital role in HR modulation. Septic patients typically develop a high fever, low BP and high HR (40) . Considering this evidence, we hypothesize that changes in temperature and pain perception observed in humans contribute to the fluctuations in HR and BP following an endotoxin challenge.
The objective of this study is to develop a mathematical model to understand the impact of variations in human inflammatory markers on thermal, pain, and hemodynamic responses. We hypothesize that LPS-induced inflammation causes fever, leading to higher HR via decreased parasympathetic activity and changes in BP-HR interactions. In addition, we hypothesize that inflammation lowers the threshold for pain perception and stimulates NO synthesis. Finally, we hypothesize that pain and NO have opposing effects on BP. More specifically, a reduced pain tolerance increases BP through increased vascular resistance, and an increase in NO leads to a decrease in BP through vasodilation.
To test these interactions, we expand upon our previous dynamic model for a systemic inflammatory reaction to LPS (7) by adding pathways for changes in temperature, pain perception, NO, HR, and BP. The model is fit to patient data from two independent clinical studies (13, 31).
We further perform simulation studies of the model's ability to capture the effects of common treatments, such as antibiotics, antipyretics, and vasopressors.
Materials and Methods

Data and Experimental Design
Study Subjects
Copeland et al. (13) administered a bolus dose of LPS to 10 human subjects. The participant group included male and female healthy adult volunteers aged 18 to 40 years. Exclusion criteria for participation included chronic disease history, e.g. cancer, rheumatoid arthritis, heart disease, and hypertension, or history of abnormalities affecting the immune system, e.g. the liver, kidneys, endocrine system, or neural system. This study was approved by the Institutional Review Board of UMDNJ-Robert Wood Johnson Medical School, all subjects gave written consent to participate.
The study by Janum et al. (31) included 20 healthy male adults ages 18 to 35 years, who received LPS. Exclusion criteria include smoking, obesity, daily intake of medication, and splenectomy.
The Regional Committee on Health Research Ethics and the Regional Data Monitoring Board approved the investigation protocol, and all participants gave written consent to participate in the study.
Experimental Protocol
Both studies followed a similar experimental protocol administering a 2 ng/kg dose of LPS derived from Escherichia coli intravenously and measuring the systemic inflammatory response, body temperature, HR, and BP. Copeland et al. (13) assessed participants over 9 hours post-injection, while Janum et al. (31) assessed subjects 2 hours before and 6 hours after endotoxin administration.
The Janum study applied a heat stimulus to the non-dominant thigh at varying temperatures (45, 46, 47, 48° C) for 5 seconds followed by a period of 32° C to evaluate pain perception. Subjects were asked to rate each heat stimulus on a scale from 0 (no pain) to 10 (worst imaginable pain).
Pain perception was measured using an algometer in which pressure was applied manually at increasing kPa. When participants indicated that their pain threshold was reached, the algometer value was recorded.
In each study, blood samples were collected to measure plasma levels of pro-(TNF-, IL-6, and IL-8) and anti-inflammatory (IL-10) cytokines. Both studies recorded systolic BP and temperature at discrete time points; standard BP was measured hourly with a BP cuff on the upper arm. The Copeland study measured HR at discrete time points, while Janum et al. (31) measured HR continuously throughout the 6-hour interval. Fig. 1 shows the detailed experimental protocol for each study. In our previous study (7) modeling the inflammatory response using the data by Janum et al. (31) , results are reported as the mean ± standard error of the mean (SEM) for each subject. The data extracted from the Copeland et al. study were reported as the average over the population. To compare the response from the two studies we validated model predictions against the population average response for each study. Moreover, to predict proper cytokine decay synthetic data was added to the Janum et al. (31) data at = 7 and 8 hours. Finally, to achieve data format consistency for BP and HR between the two studies, we sampled HR and BP measurements at the same time-points.
FIG. 1 -DATA DESCRIPTION
Mathematical Model Development
Our mathematical model (shown in Fig. 2 ) includes three sub-models of 1) the inflammatory response to endotoxin, 2) the effect on temperature, pain perception, and nitric oxide, and 3) their effect on the cardiovascular system. Below we describe each component and their interdependencies.
FIG. 2 -FEEDBACK DIAGRAM FOR HUMAN RESPONSE TO LPS
Part I: The inflammatory response to an endotoxin challenge
Monocytes and macrophages use cytokine signaling to communicate in response to a pathogen and are an essential part of innate immunity. Bone marrow stem cells differentiate into monocytes and move into the bloodstream. From here they enter the connective tissue matrix where they differentiate into macrophages, which interact with the cytokines (44) . Monocytes and macrophages are normally at rest, but with a bacterial stimulus (e.g. from LPS) the number of macrophages increases by several orders of magnitude.
Cytokines are potent signaling molecules that regulate many processes essential to immunity and inflammation. In (7), we constructed a classic kinetic model of the systemic inflammatory response to an endotoxin challenge, incorporating signaling pathways illustrated in Fig. 3 (equations are given in the Appendix). We extend this model to include thermal, pain, nitric oxide, and hemodynamic models and calibrate it to inflammatory mediator data from the studies by Janum et al. (31) and Copeland et al. (13) .
FIG. 3 -INTERACTIONS AMONG IMMUNE COMPONENTS
Part II: The thermal, pain and nitric oxide response Thermal effects. The binding of LPS to receptors on macrophages and other immune cells stimulates the production of pyrogenic (fever-inducing) cytokines IL-6, TNF-, and IL-1 , which act to induce and maintain fever. These pyrogens stimulate afferent vagal nerves terminating in the brain, and this relays information to the hypothalamus about the ongoing inflammation and triggers the release of prostaglandins. Prostaglandins act on neurons in the preoptic nucleus of the hypothalamus, which is the area responsible for temperature regulation (12, 36) . TNF-is a potent pyrogenic cytokine, and it is one of the main cytokines implicated in septic shock. IL-6 has recently been shown to be necessary to sustain fever (16, 24) . Conversely, IL-10 has antipyretic effects, lowering temperature (12, 43) .
To account for this feedback, we introduce temperature regulation modeled as a function of TNF-and IL-6, which upregulate temperature, and IL-10, which counteracts these effects. 
Temperature is modeled as
where Temp is temperature, 5 but they can also be activated by bacteria directly. Previous studies (2, 31, 63) show that there is a dose-dependent relationship between pain perception and inflammation. We model the threshold for perception of pain as
where _7\ and _7 are rate constants and 5 is the baseline pain threshold. Upon injection, the endotoxin (E) decreases exponentially, resulting in a decrease in the pain perception threshold (59). As the body clears endotoxin, the pain perception threshold returns to baseline.
Nitric Oxide (NO).
The endothelium cells lining the blood vessels uses nitric oxide (NO) signaling to interact with nearby smooth muscle cells, which relax with increased release of NO (37) . NO has direct and indirect microbial effects including inhibition of pathogen proliferation (3, 4, 58) .
As part of the inflammation pathway, upon signaling from TLRs or inflammatory cytokines, macrophages produce inducible nitric oxide synthase (iNOS) which affects their phenotype and leads to the production of NO (39) . TNF-upregulates the NO production (51) and IL-10 downregulates its synthesis (9, 25 
In this equation represents the delay in activation/inhibition of NO from TNF-and IL-10, a8
and a are rate constants, and a:;< , a0H , ℎ a:;< , and ℎ a0H are Hill function parameters determining the half-saturation value and steepness of the response.
Part III: Impact of the immune response on cardiovascular dynamics
The cardiovascular system is continually modified to maintain homeostasis (ensuring adequate oxygen perfusion at stable resting BP). The body maintains this state via the autonomic control system regulating vascular compliance, resistance, and cardiac contractility and HR. The baroreflex branch of the autonomic control system consists of parasympathetic and sympathetic signaling primarily responding to changes in BP. The vagal nerve is the primary pathway for the parasympathetic signaling. An increase in parasympathetic signaling leads to a decrease in HR (62) . This response is caused by release of acetylcholine primarily at the level of the sinoatrial node. Preganglionic sympathetic nerve fibers travel through the spinal cord synapses with the postganglionic fibers and thus transmit the sympathetic signals, stimulating the release of noradrenaline, which causes smooth-muscle contraction, increasing the peripheral vascular resistance and decreasing the compliance of the vascular wall. The baroreflex response to changes in BP acts within seconds to minutes, but basal activity in both efferent pathways (parasympathetic and sympathetic) are present even in the absence of a stimulus (change in BP). We hypothesize that the basal activity level may be modulated by several factors including fever and pain perception (21, 32) . In addition to neural response, the vascular system is also controlled locally, e.g., in response to changes in NO, which is a potent vasodilator and through release of catecholamines form the adrenal medulla. To model this feedback, we develop a simple cardiovascular model coupled with control for modulating HR and peripheral vascular resistance, impacting prediction of BP.
Cardiovascular Model
Due to significant BP and HR changes taking place over the course of hours, the current model does not account for respiratory dynamics. Therefore, we limit the cardiovascular model to the systemic circulation, which we model as a series of compliance (C) and resistance (R) elements using an electric circuit analogy. Our model (shown in Fig. 4 ) consists of four compliance compartments representing the large and small arteries and veins. Three resistance elements separate these compartments, including the resistance provided by the systemic organs and the pressure gradient between the large and small arteries and veins. The model is non-pulsatile since the relevant timescale for all model variables is hours, i.e. the pumping of the heart is not explicitly incorporated (65).
The predicted variables are flow ( / ), volume ( ), and pressure ( ). The model is formulated using four differential equations describing conservation of volume via
where yz is flow entering the compartment, and {|} is flow leaving the compartment. Between two compartments, flow is related to pressure via Ohm's law given by
where yz and {|} (mmHg) denote the pressure in the two surrounding compartments and y (mmHg s/mL) is the resistance to flow.
Finally, for each compartment, pressure ( ) is related to volume ( ) via a pressure/volume relation
where }y‚ (mmHg) is the tissue pressure, is the elastance, and |z is the unstressed volume. We drive the cardiovascular model by a "non-pulsatile heart" tracking stroke volume ‚}ƒ via
where (beats/min) is the HR, and (mL/s) is the cardiac output. ‚}ƒ , the volume of blood the heart pumps out during one beat, is computed by
where \I is the end-diastolic volume in the heart, \ † is the end-systolic volume, ˆ‰ is pressure in the large arteries, ˆŠ is pressure is pressure in the large veins, and 8 and ‹ are the maximum and minimum elastance, respectively (1). The Appendix gives a complete list of model equations.
FIG. 4 -CARDIOVASCULAR MODEL
Cardiovascular Control Model. As noted earlier, the cardiovascular control system modulates several vascular parameters including peripheral vascular resistance ( † ), cardiac contractility (here represented by ‹ and 8 , vascular compliance ( ), and heart rate ( ). Given the lack of pulsatilility in the model and data, we focus on describing regulation of vascular resistance and heart rate. In this system, vascular resistance ( † ), on the timescale studied here, is primarily controlled by pain via sympathetic stimulation, which up-regulates † , and nitric oxide which down-regulates † . In response to LPS, the pain perception threshold decreases, upregulating the peripheral vascular resistance between the small arteries and veins via sympathetic stimulation.
Resistance is downregulated by NO. To capture these effects, we model the peripheral vascular resistance as
where
is the rate of change of the pain perception threshold and 5 is the baseline peripheral vascular resistance (before the LPS injection) in the absence of pain and nitric oxide (Γ = 0 and = 0). The rate constants are given by Ž_7 , Ža , and Ža . The half-saturation value of the Hill function is given by Ž_7 Upon administration of endotoxin, the pain threshold decreases, resulting in an increase in Γ • and consequently ‚ . As LPS decays and PT returns to its baseline value, Γ • approaches zero. NO begins to rise two to four hours after the initial inflammatory response, causing ‚ to decrease.
The changes in peripheral vascular resistance lead to changes in BP. Elevated vascular resistance, brought about by stimulation of the sympathetic system in response to increased pain perception, leads to a rise in BP. On the other hand, a high NO concentration notably lowers resistance through vasodilation, which can lead to an excessive drop in BP (50).
Due to activation of the baroreflex, the increase in BP leads to a decrease in HR, while during hypotension, the excessive BP drop causes an increase in HR. Also, with fever induction as a consequence of the pyrogens released by monocytes, the CNS decreases basal vagal tone, which increases HR (32) . To predict these responses in HR dynamics, we model HR as follows
We prescribe a switching systolic BP level of 100 mmHg since the hypotension cutoff value can range between 90 mmHg and 117 mmHg, depending on age (42) . HR will increase in response to hypotension, which is supported by the observation that when BP is low HR rises to compensate for reduced cardiac preload resulting from vascular dilation (23) . Otherwise, BP would act to lower HR. Both effects depend on temperature elevated above its baseline level. In sum, we are proposing that BP impacts HR on the time scale of hours during infections, but not in the absence of fever under normal circumstances.
Model Summary
The model described above can be written in the following form 
The elements of are: 
Nominal Parameter Values
As described above, the model is comprised of three sub-models, namely the inflammatory, regulatory, and cardiovascular models. For each clinical study, we select a nominal parameter set which generates model dynamics that qualitatively align with the data trends.
Inflammatory sub-model: For Janum et al., parameter values for the inflammatory sub-model
were taken from (7). For Copeland et al., parameters were adapted from (7), with several values being adjusted to achieve a better alignment between the model outputs and the data. Among the parameters that differ between the studies are the baseline levels of cytokines, the IL-6 synthesis in response to TNF-, the rate at which TNF-activates monocytes, and the monocyte production rate of TNF-and IL-6. See Table 2 for a complete list of the parameters different between the two studies.
Cardiovascular sub-model:
For both studies we calculate the cardiovascular parameters as described in (6) . The values for elastance in each compartment ( y ) and minimum and maximum elastance ( ‹ and 8 ), presented in Table 2 , are computed with the following equations:
where ‚},y is the stressed volume and |z is the unstressed volume in compartment . The enddiastolic and end-systolic volume in the heart are given by \I = 142 − |z , \ † = 47 − |z , with |z = 10 (6).
The calculation of ‚},y assumes that systemic volume is 85% of total blood volume, while the arterial and venous volumes are 20% and 80% of systemic volume, respectively (6) . Total where ℎ (cm) is height and (kg) is weight (6) .
Regulatory sub-model: For both studies, the parameters in the regulatory sub-system are adapted from (6) and adjusted where necessary to align with the data (Table 2) . We set the parameters representing the baseline levels of temperature, HR, and BP ( 5 , 5 , and 5 , respectively) to the initial points in the data sets, that is, the measurements at = 0. The equations for temperature and HR also have maximum level parameters ( 8 and 8 , respectively) which are informed by the literature. 8 is 39.5° C, the cutoff for life-threatening hyperthermia (48) , and 8 is 207 (beats/min) (20). In addition, the delay κ in the NO equation is chosen to ensure that an increase in NO is observed two to four hours after LPS administration (34) .
Parameter Estimation
We fit the model to the measurements available for immune mediators, temperature, BP and HR, by minimizing the least squares error between the model output and the data averaged over the population of healthy subjects in each study. The least squares error is given by
where ´±Ä³ ¶ and Äµ°µ are the model output and measured data, respectively. Äµ°µ ÅÅÅÅÅÅ is the mean of the data, and is the total number of data points (38) . For this study, we minimize using the built-in optimization routine fminsearch in MATLAB.
To determine which parameters to estimate, we used sensitivity analysis and subset selection for each sub-system of our mathematical model. Sensitivity analysis was carried out using a local derivative-based approach where parameters are varied one at a time to determine the sensitivity of the model output to its parameters. If small perturbations in a parameter result in significant changes in the output, the parameter is sensitive. If not, then the parameter is insensitive. The relative sensitivity was computed with a forward difference approximation, as described in (33) and ranked sensitivities were computed using the two-norm averaging time-varying sensitivities to find a group of sensitive parameters for each sub-model.
After a set of sensitive parameters was identified, we used subset selection by the correlation method outlined in (41) to determine which of the sensitive parameters were identifiable. A parameter is unidentifiable if it has a linear dependence on the values of other parameters. The parameters we estimated (given in Table 3 ) were ones that were both sensitive and identifiable. A detailed presentation of the sensitivity analysis and subset selection is given in (6) gives a detailed presentation of the sensitivity analysis and subset selection. Since the sensitivity matrix is evaluated at the nominal parameter values, this analysis is only valid in a neighborhood around the nominal values. Therefore, we repeated the subset selection at the optimized parameters to ensure that the estimated parameters are still identifiable.
Therapeutic Interventions
We use the physiological model to carry out an in-silico exploration of several therapeutic To model an infection state, we let the endotoxin to remain constant over a 12-hour time window. This approach simulates the situation when the body is not capable of clearing the pathogen from the bloodstream on its own (50) . This causes the systolic BP to fall to a hypotensive level (below 90 mmHg) (42, 60) . This state only arises after a prolonged period of inflammation not examined in the Copeland and Janum studies, who only considered the response to a bolus LPS injection resulting in controlled inflammation where systolic BP rises slightly in response to endotoxin and then decreases back toward the nominal level. By adding the simulation of infection,
we show that our model can account for the physiological response during controlled inflammation as well as for the case of hypotension.
We captured the action of antibiotics by increasing the decay rate of LPS ( \ ). The time frame for initiating antibiotic administration considers that medical intervention is not used before the infection has resulted in a significant rise in temperature. A commonly used indicator is fever, and the peak in body temperature occurs at about 4 hours. We modeled antipyretics by changing the PT and temperature dynamics, allowing them to reach baseline levels faster, and vasopressors by increasing the rate at which resistance approaches its baseline level, which in turn affects BP.
Lastly, we look at a combined therapeutic protocol, that targets LPS, pain and fever, and resistance simultaneously. The Appendix gives a detailed description of the implementation of these therapeutic interventions.
Results
Parameter Estimation
We apply the physiological mathematical model to the two datasets. hours, which acts to decrease HR, but the temperature effect dominates the dynamics, and HR remains elevated above baseline.
After fitting the model to data, we discovered that temperature alone is not enough to explain the HR dynamics. We observed that elevated temperature increases HR, but the subsiding of fever did not lead to a decrease in HR as seen in the data (Fig. 6 ). This indicates that, apart from temperature, there must be another HR control mechanism causing the restoration of homeostasis, and our findings suggest that BP could be this control mechanism.
We first tested an equation structure for the HR variable, where temperature and BP were accounted for as independent effects, by adding their contributions. The results (Fig. 6 ) reveal that this model does not fully capture the dynamics of the observed HR response. This led us to hypothesize that the effects of BP on HR, on the time scale of hours, are temperature-dependent, and the model fits to the data confirm this hypothesis.
FIG. 5 -MODEL FITS TO DATA
FIG. 6 -TEMP ALONE & INDEPENDENT TEMP AND BP EFFECTS Therapeutic Interventions
We further probe the validity of the mathematical model by using it to predict responses to treatments. We examine the model predictions in the case of a sustained inflammatory event causing an infection as well as the effects of different treatment alternatives, including antibiotics, antipyretics, vasopressors, and a therapy combining all three medications. Results of these simulations are summarized in Figs. 7 and 8.
Infection State
Infection can be described by a sustained inflammatory event where the immune cells are ineffective at clearing it from the bloodstream. The physiological response to an untreated infection includes a significant increase in HR and a drop in BP, which in severe cases fall to a hypotensive level (defined as a systolic BP at rest below 100 mmHg).
An infection dramatically decreases the number of resting monocytes, leading to a higher level of activated monocytes, compared to the case of a controlled inflammatory response (Fig.   S1 ). The pro-inflammatory cytokines peak earlier in the presence of an infection when compared to baseline. However, they reach similar maximum concentrations. The anti-inflammatory cytokine IL-10 reaches a notably higher level, and this translates into a slightly lower peak in temperature since IL-10 suppresses the thermal response. The temperature does not return to its nominal level as it does in a normal inflammatory response (Fig. 7) due to the slow decay of pyrogens.
The sustained presence of LPS during infection also causes a significant drop in the pain threshold. NO concentrations are higher due to release from the increased number of activated monocytes (Fig. 7) . These response indicators have opposite effects on resistance. The initial change in PT is more dramatic than the increase in NO, resulting in a more significant increase in resistance when compared to the response in the absence of infection. However, after 4 hours, the rate of PT decline is slow, while NO is still sufficiently elevated. This results in a decreasing resistance. The rise in resistance leads to a higher BP than in the case of a normal inflammatory response, including the maximum value. As the resistance drops, a notable decrease occurs in BP, bringing it in a hypotensive range, which persists.
In response to an infection, our simulation results (Fig. 7) show a significant increase in HR as a temperature rises. The maximum HR reached is like that in a normal inflammatory response.
As the thermal response subsides, HR begins to decrease with further downregulation from BP.
However, as BP decreases into the hypotensive range, HR increases again to compensate for reduced blood circulation (23) .
Antibiotics
In this scenario, the bacterial toxin has a sustained presence for 4 hours, and then antibiotics are administered to accelerate its clearance from the bloodstream. Antibiotics are a standard treatment used to fight bacterial pathogens (22, 50). Intervening with antibiotics prompts a slow recovery in the PT and helps to bring temperature and HR down toward their nominal levels. On the other hand, BP increases slightly, but there is no significant improvement toward recovery from the hypotensive range (Fig. 7) . This is due to the introduction of antibiotics after the number of activated monocytes reaches a peak. The large cell population results in elevated NO, which has a stronger influence on the cardiovascular system compared to the change in PT.
Antipyretics
Fever is usually a part of the body's response to infection as well as an element in the inflammation from other causes. In the intensive care unit, about 70% of patients experience fever (11) . In addition, surgical procedures are associated with a noticeable increase in body temperature (19).
Antipyretic medication is a commonly used therapeutic approach for managing fever and pain to lessen the strain on the cardiovascular system and improve patient recuperation outcomes (53) . As with antibiotics, introducing antipyretics into the model leads to recovery in HR. On the other hand, there is a moderate improvement in BP but only for a short time following antipyretic administration (Fig. 7) . Then, BP falls to the hypotensive rage and does not recover. Also, the BP level decreases more compared to the case of antibiotic administration. This is due to NO being sufficiently elevated and exerting a stronger effect on peripheral vascular resistance than the change in PT. As antipyretics do not directly affect endotoxin levels, the inflammatory mediators and NO remain as in the infectious state. In addition, the decrease in HR causes further drop in BP due to lower cardiac output.
Vasopressors
The inflammatory response to an infection results in increased nitric oxide production (50) , which leads to a significant drop in systemic blood pressures. Vasopressors may be used to elevate these pressures to a normal level (22, 49, 50) . Like antipyretics, vasopressors do not affect endotoxin levels, resulting in no change in inflammatory mediators, NO, PT, or temperature. The action of vasopressors increases resistance, which translates into recuperation of systolic BP to its nominal level. Despite this, HR remains abnormally elevated (Fig. 7) .
Multimodal Treatment
The multimodal therapeutic strategy simultaneously targeting toxin clearance, pain and fever, as well as low resistance, renders the best outcome since it brings about the alleviation of pain as well as recovery of normal body temperature, HR, and BP (Fig. 8) .
FIG. 7 -ANTIBIOTICS, ANTIPYRETICS, AND VASOPRESSORS
FIG. 8 -MULTIMODAL TREATMENT Discussion
The model successfully captures the immuno-pain-thermal-cardiovascular behavior and their interactions in two clinical studies of healthy adults under an LPS challenge. In response to an inflammatory reaction against a bacterial toxin, the model shows elevation of body temperature to a febrile level that we hypothesize leads to a notable rise in HR. These results are consistent with the data, Foteinou et al. (18) and our previous observations (7) that inflammation leads to an increased HR. While the study by Foteinou et al. hypothesized that the HR increase resulted from amplified efferent sympathetic activity and diminished parasympathetic activity, the study did not elucidate the role of temperature. Additionally, the study only indirectly accounted for the pain response through the inclusion of a sympathetic activity variable.
Inclusion of the thermal component into the current model illustrates the immune system's impact on HR via the febrile response. The release of inflammatory cytokines, in particular, IL-6 and TNF, raises core body temperature (61) . Our findings suggest that the thermal response is an integral part of the interaction between BP and HR during an infection, on a time scale of hours, providing support for our hypothesis that during fever while BP is in a normotensive range, BP acts to lower HR, and when the temperature is at its baseline level, no dramatic HR fluctuations are observed.
Our model directly addresses the role of the pain pathway in the human response to endotoxin. Using data and observations from Janum et al. (31) our model reveals that the body's pain threshold diminishes during an endotoxin challenge. In addition, our investigation shows that the pain response is linked to cardiovascular dynamics and leads to a slight increase in BP in the early stages of the inflammatory reaction.
Therapeutic Interventions
The onset of an infection initiates a cascade of physiologic reactions acting at multiple timescales, complicating critical care for the patient. This study performs a simulation-based treatment investigation to predict the impact of several interventions commonly used in the clinical management of infection. We simulate an infection by keeping the endotoxin level constant, simulating the body's inability to effectively remove the endotoxin (50) . The model predicts detrimental pathophysiological effects of sustained LPS presence including fever, increased sensitivity to pain, hypotension, and elevated HR. These results are consistent with the symptoms observed in sepsis (40) . However, it should be noted that in septic patients who have a Gramnegative infection, the LPS level is much higher than the 2 ng/kg dose used in the clinical studies.
Antibiotics are typically used to treat bacterial infections. In the management of sepsis, broad-spectrum antibiotics are given to patients intravenously to combat the spreading pathogen and reduce the bacterial endotoxin level (22, 50). The simulation results from our model demonstrate that antibiotics lead to fever reduction, pain relief, and HR normalization, but not a notable improvement in BP.
Antipyretics are used to reduce core body temperature and pain (46) . This treatment, however, does not block the dynamics of inflammatory cytokines (55) . According to (46) , the benefits and drawbacks of such medication are not well understood. Fever may serve an essential role in fighting the infection, but it may also negatively impact the cardiovascular system. Our findings indicate that while antipyretics favorably affect pain, body temperature, and HR, they are unable to reverse hypotension. Vasopressors are an alternative treatment option that targets the cardiovascular system. The simulation analysis illustrates that vasopressors are successful in normalizing systolic BP, but they fail to alleviate fever, pain, and reverse abnormally high HR.
Uncontrolled infection, which spreads and leads to sepsis, is a multifaceted condition with numerous possibilities for treatment, as seen in its pathophysiology and recent treatment guidelines (26, 27) . Considering this, a multimodal treatment strategy was simulated, where antibiotics, antipyretics, and vasopressors are introduced simultaneously into the system. As the model captures complex interactions among immune, thermal, pain, and cardiovascular components, the goal was to assess how the combined administration of interventions impacts the predicted behavior and compares with the outcomes from the individual treatment administrations. Our results demonstrate that when combined, antibiotics, antipyretics, and vasopressors affect the model variables in essentially the same way as they did independently. Vasopressors act to restore normal BP, antipyretics restore PT and temperature, and the HR trends to its baseline value.
Overall, this in-silico assessment shows that the combination treatment is the most effective way to relieve pain and bring about the recovery of normal temperature, HR, and BP. While these results are promising, future work is needed to understand how the medications act either synergistically or in competition to counteract an inflammatory event.
The data fitting and simulation analysis demonstrates that the model provides a platform to explore how specific biological pathways affect predicted cardiovascular outputs. There is an advantage in tracking the cardiovascular response through HR and BP since these quantities can be measured non-invasively and interpreted within minutes, allowing for a much quicker patient assessment compared to blood sampling to determine plasma levels of pro-inflammatory cytokines.
Limitations and future work
A limitation of our model is that it is calibrated over a short time course dictated by the time scale of the two endotoxin clinical studies, of duration 9 hours and 6 hours. This makes it difficult to assess its ability to track dynamics over days, which is needed to understand the response to an infection. Moreover, we only analyze data from a small number of subjects (10 and 20, respectively) increasing the uncertainty of model predictions.
In addition, there are several simplifying assumptions within the model. First, we assume that the endotoxin decays at a linear rate and is otherwise uncoupled from the rest of the model. This model is appropriate for studying the endotoxin response to a bolus LPS injection, but the model needs additional components to predict the response to treatment. In future studies, we will investigate the interactions among activated macrophages, pathogens and fever since there is evidence suggesting that aggressive treatment for body temperature higher than 38.5°C can negatively affect the recovery of critically ill patients, decreasing their ability to successfully clear infections (53) . Furthermore, fever is beneficial in combating pathogens by limiting their reproduction, increasing the activity of many classes of antibiotics, and increasing the innate immune response (61) .
Other Simulation results show that to remedy these detrimental effects, the most effective approach is to administer a multimodal treatment combining antibiotics with antipyretics and vasopressors to simultaneously target toxin, pain, fever, and low vascular resistance.
Inflammatory Response
The equations of the inflammatory response are given by 
where the up-and down-regulation of Y by X is modeled using the Hill functions, R > ( ) = 
Cardiovascular Response
By conservation of volume, the changes in volume in the large and small arteries and veins are
The flow through each compartment is found using Ohm's law giving
where ‰ and Š are arterial and venous resistances, and ‚ is the peripheral vascular resistance.
For each cardiovascular compartment, the pressure and volume are related by
where y is the volume of the compartment, |z is the unstressed volume, y is the elastance of the compartment, y is the pressure in the compartment, and }y‚ is the tissue pressure.
Therapeutic interventions
We perform a theoretical therapy study over a 12-hour time window.
Infection State:
To simulate an infection, we assume the amount of endotoxin ( ) remains constant for 12 hours, i.e.
= 0.
Antibiotics are administered four hours after the onset of the infection to mimic typical action of patients seeking help once they experience fever. We hypothesize that antibiotics will increase the rate at which the endotoxin clears from the bloodstream and model this as
That is, there is a constant, sustained endotoxin presence initially, which begins to decay once the antibiotics are introduced at = 4. The rate at which this occurs is set to be twice as fast as the endotoxin would decay during an inflammatory event without intervention with an antibiotic.
Antipyretics are also introduced into the model at 
Multimodal Treatment also initiated 4 hours after the infection onset combines antibiotics, antipyretics, and vasopressors combining the models in (5-8). Temperature increases heart rate (HR). BP decreases HR, via changes in vagal tone, in the case of normotension. When BP falls to a hypotensive range, it will act to increase HR. The changes in HR via BP are temperature-dependent. Effect on heart rate dynamics of temperature alone and of temperature and blood pressure as independent effects for the (A) Copeland and (B) Janum studies. Temperature alone (blue curves) results in an increase in heart rate, however it is not sufficient alone to return heart rate to its baseline level. Including temperature and blood pressure as independent effects (red curves) also does not fully capture the dynamics of the observed heart rate response. Antibiotics (blue curves) result in a decrease in the endotoxin, pain relief (increase in PT), fever reduction, and heart rate normalization (the increase in heart rate between = 4.5 and = 5 is due to blood pressure being in the hypotensive range during that time). Antipyretics do not affect the endotoxin; however, they induce pain relief and decrease fever and heart rate. They are unable to counter hypotension. Similar to antipyretics, vasopressors do not affect the endotoxin. While they do not alleviate fever, pain, or abnormally high heart rate, they are able to normalize blood pressure. These pro-inflammatory mediators stimulate the production of IL-10, which regulates the immune response as an anti-inflammatory mediator. IL-6 also exhibits anti-inflammatory effects as it downregulates the synthesis of TNF-α and its own release. Fig. 4 . Cardiovascular model. The cardiovascular system is comprised of the small and large arteries and veins (subscripts sa, la, sv, lv). Each compartment has an associated blood pressure p (mmHg), volume V (mL), and elastance E (mmHg/mL). Flow between compartments are represented by qi (s/mL), with a corresponding resistance Ri (mmHg s/mL) with subscripts (a, s, v) representing arteries, veins, and peripheral vasculature. . Endotoxin (2 ng/kg) was administered at time = 0 and inflammatory mediator response, temperature, heart rate, and blood pressure were recorded over 9 hours (A-B) and 6 hours (C-D). Fig. 6 . Effect on heart rate dynamics of temperature alone and of temperature and blood pressure as independent effects for the (A) Copeland and (B) Janum studies. Temperature alone (blue curves) results in an increase in heart rate, however it is not sufficient alone to return heart rate to its baseline level. Including temperature and blood pressure as independent effects (red curves) also does not fully capture the dynamics of the observed heart rate response. Fig. 7 . Effect of antibiotics, antipyretics, and vasopressors on cardio-inflammatory response. After inducing an infection via a constant endotoxin (black curve) (A), interventions were simulated at = 4 (red dashed line). The infection causes (B) a slight decrease in temperature and (C) a dramatic decrease in the pain perception threshold. (D) Nitric oxide rises in response to the infection and does not respond to any intervention. (E) The resistance increases in response to the infection, resulting in (F) an increase in blood pressure and a subsequent (G) decrease in heart rate. Antibiotics (blue curves) result in a decrease in the endotoxin, pain relief (increase in PT), fever reduction, and heart rate normalization (the increase in heart rate between = 4.5 and = 5 is due to blood pressure being in the hypotensive range during that time). Antipyretics do not affect the endotoxin; however, they induce pain relief and decrease fever and heart rate. They are unable to counter hypotension. Similar to antipyretics, vasopressors do not affect the endotoxin. While they do not alleviate fever, pain, or abnormally high heart rate, they are able to normalize blood pressure. 
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